In experiments performed at the Malmoe University Hospital in Sweden, researchers showed that NOLabs’ technology has a promising ability to kill a wide range of pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
Goran Beijer, CEO of NOLabs, said: “The anti-microbial effect of NO will be key in several products that will prevent or treat infection depending on dosing. We are now accelerating our development program and expect to have the first products on the market during 2008.”